Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
复制标题
DOI：
10.1200/jco.1996.14.6.1848
复制
发表时间：
1996-06-01
影响因子：
45.3
通讯作者：
Schwaiger, M
中科院分区：
文献类型：
--
作者：
Avril, N;Dose, J;Schwaiger, M
Purpose: To evaluate the diagnostic value of positron emission tomographic (PET) imaging with F-18 fluorodeoxyglucose (FDG) in differentiating between benign and malignant breast tumors.Patients and Methods: Fifty-one patients, with suspicious breast lesions newly discovered either by physical examination or by mammography, underwent PET imaging before exploratory surgery. FDG-PET images of the breast were analyzed visually and quantitatively for objective assessment of regional tracer uptake.Results: Primary breast cancer was identified visually with a sensitivity of 68% to 94% and a specificity of 84% to 97% depending on criteria used for image interpretation, Quantitative analysis of FDG uptake in tumors using standardized uptake values (SUV) showed a significant difference between benign (1.4 +/- 0.5) end malignant (3.3 +/- 1.8) breast tumors (P < .01). Receiver operating characteristic (ROC) curve analysis exhibited a sensitivity of 75% and a specificity of 100% at a threshold SUV value of 2.5. Sensitivity increased to 92% with a corresponding specificity of 97% when partial volume correction of FDG uptake was performed based on independent anatomic information.Conclusion: PET imaging allowed accurate differentiation between benign and malignant breast tumors providing a high specificity. Sensitivity for detection of small breast cancer (< 1 cm) was limited due to partial volume effects. Quantitative image analysis combined with partial volume correction may be necessary to exploit fully the diagnostic accuracy. PET imaging may be helpful as a complimentary method in a subgroup of patients with indeterminate results of conventional breast imaging. (C) 1996 by American Society of Clinical Oncology.
